Associations of aspirin and other anti-inflammatory medications with mammographic breast density and breast cancer risk
Menée à partir des données des cohortes "the Nurses’ Health Studies" portant sur 3 675 femmes, cette étude analyse l'association entre une utilisation d'aspirine ou d'autres anti-inflammatoires non stéroïdiens et la densité mammaire ou le risque de cancer du sein
Purpose: We investigated the associations of aspirin and other non-steroid anti-inflammatory drugs with mammographic breast density (MBD) and their interactions in relation to breast cancer risk. Methods: This study included 3,675 cancer-free women within the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII) cohorts. Percent breast density (PD), absolute dense area (DA), and non-dense area (NDA) were measured from digitized film mammograms using a computer-assisted thresholding technique; all measures were square root-transformed. Information on medication use was collected in 1980 (NHS) and 1989 (NHSII) and updated biennially. Medication use was defined as none, past or current; average cumulative dose and frequency were calculated for all past or current users from all bi-annual questionnaires preceding the mammogram date. We used generalized linear regression to quantify associations of medications with MBD. Two-way interactions were examined in logistic regression models. Results: In multivariate analysis, none of the anti-inflammatory medications were associated with PD, DA, and NDA. We found no interactions of any of the medications with PD with respect to breast cancer risk (all p-interactions > 0.05). However, some of the aspirin variables appeared to have positive associations with breast cancer risk limited only to women with PD 10–24% (past aspirin OR 1.56, 95% CI 1.03–2.35; current aspirin with < 5 years of use OR 1.82, 95% CI 1.01–3.28; current aspirin with ≥ 5 years of use OR 1.89, 95% CI 1.26–2.82). Conclusions: Aspirin and NSAIDs are not associated with breast density measures. We found no interactions of aspirin with MBD in relation to breast cancer risk.